WhatsApp: From Skeptic to Believer—How It’s Building Communities
When I first considered WhatsApp as a professional communication channel, I was deeply skeptical. It felt too informal, too personal.
The problem with POL
Probability of Launch (POL) is a comprehensive metric designed to estimate the likelihood that a drug successfully completes all clinical
The problem with DCF
1. Introduction: The Biotech Valuation Maze
Biotech valuation is fraught with complexities that standard financial tools like Discounted Cash Flow
The problem with PRS
Probability of Regulatory Success (PRS) is a metric used to estimate the likelihood that a drug candidate will successfully navigate
On Sitting on the Sidelines: Why Calling Out the Problems Isn’t Enough
Every so often, I wonder if I’m shouting into the void. Not in the performative, social media outrage kind
A Forensic Guide: Using Extreme Value Theory (EVT) to Find Weaknesses in Pharma and Biotech Pitch Decks
When a venture capital (VC) firm or a legal team evaluates an early-stage biotech or pharma startup, due diligence is
The LinkedIn Humblebrag: A Study in Digital Narcissism
LinkedIn. The once-practical platform for professional networking has evolved into a peculiar blend of motivational seminar, humblebrag arena, and corporate
The Graveyard of Innovation: Pharma’s Survivorship Bias
I have a confession to make: I’m fascinated by failure. Not in a morbid, schadenfreude sort of way, but
Mentoring: A Marathon, Not a Shortcut
Mentoring: It’s Not Just a LinkedIn Title
Mentoring is having a moment. If you’ve scrolled through LinkedIn recently,
Overall Survival: The Gold Standard Under Scrutiny
Overall survival (OS) has long been considered the gold standard in oncology trials. Defined as the time from treatment initiation
